NemaGen Discoveries is an early phase biotech company based in Princeton, NJ, dedicated to advancing therapies for patients suffering from allergic inflammation and mast cell-related diseases. Through their innovative research on the body's natural ability to prevent inflammation after parasitic infections, NemaGen has developed groundbreaking technologies and therapeutic strategies to address a wide range of inflammatory conditions.
With a focus on drug development, NemaGen is actively involved in the NIH I-Corps program to engage with stakeholders and validate the value of their therapies. As a pioneering force in the field, NemaGen Discoveries is committed to making a significant impact on the lives of patients affected by inflammatory diseases.
Generated from the website